Nucleus Network Nucleus Network Nucleus Network Nucleus Network Nucleus Network Nucleus Network Facebook Instagram Twitter Linked In Weibo Wechat Facebook Linked In WeChat Sina Weibo Email Phone Next Scroll to move Touch to move edit edit Play Play Pause Volume Mute Zoom Beds Baths Carports

Home

Nucleus Network acquires majority shareholding in US-based Prism Clinical Research

Nucleus Network expansion creates first global, multi-site early phase trial organization with investment in USA-based phase I clinical trials organisation, Prism Clinical Research.

Studies Approved within 4-5 weeks of IRB Submission

Australia’s Clinical Trial regulatory process doesn’t require an IND or IMP

Record Audit Performance

Our facilities and processes have been FDA & EMA Inspected and previously ANVISA Certified

Financial Incentives for R&D in Australia 

Take advantage of Australia’s favourable exchange rates and internationally-accessible R&D Incentive Scheme

Melbourne, Australia: Culturally Diverse and Highly Innovative 

Over 140 cultures represented, and some of the best healthcare in the world, makes our city a top destination for Clinical Trials

Our Reputation is Driven by Repeat Business

Learn why we are the most trusted Phase I Clinical Trials facility in Australia

Clinical trials unaffected by wildfires

At Nucleus Network, we’re in the business of advancing human health, wellbeing and quality of life. That’s why we’re committed to helping Australian’s impacted by the recent wildfires by raising much-needed funds and getting those to impacted communities and front-line charities.

As for our vital role of conducting clinical trials, it’s business as usual.

Our two clinical centres, in Melbourne and Brisbane, are co-located with major hospitals in their respective central business districts. The wildfires afflicting parts of Australia are located in rural and country areas, well away from the central business districts. Air quality and travel within – or to – Melbourne and Brisbane remain largely unaffected. To put this in context, Australia is the equivalent size of continental USA: the fires are well outside our Brisbane and Melbourne city locations.

aust-usa-map

Image Credit: The Australian Government.
Source: http://www.anbg.gov.au/maps/aust-usa-map.jpg

Nucleus Network trials continue unimpeded, and with peak tourism underway, our participant uptake is extraordinarily robust. To discuss conducting your next clinical trial, within Australia or at our Minnesota centre, contact our CEO Cameron Johnson.

If you would like to be part of the Nucleus Networking wildfire fundraising, reach out to our marketing team: marketingteam@nucleusnetwork.com.au

First-In-Human studies approved within 4-5 weeks of IRB submission; no IND or IMP required for Australia

Regulatory Process

Accelerated Clinical
Development Path

FDA & EMA inspected, previously ANVISA certified, with record independent audit performance and robust QA systems

Quality Standards

Quality Standards
& Audit History

Access Australia's favourable international currency exchange rates, and R&D incentives

R&D Incentive Scheme

Financial
Incentives

Largest, dedicated Early Phase Clinical facility in Australia, with a strong track record across simple and complex studies

Our experience

Unrivalled
Experience

On-site pharmacy and lab capabilities, including clean rooms for compounding and API manufacture

Our Services And Capabilities

Specialist Capabilities

Co-located with major medical research precinct and tertiary hospital campus and unique access to medical expertise

Our Locations

Premier Location

Based in Melbourne with vast multicultural, student and patient populations

Our Locations

Diverse Participant Pool

Repeat clients account for more than 80% of our revenue

About Us

High Repeat Clients

Internationally-experienced management team and highly skilled workforce

Executive Team

Executive Team

Learn more about conducting Clinical Trials with Nucleus Network

 

Loading...